Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
-1.61% $6.11
America/New_York / 18 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 801.50 mill |
EPS: | -2.79 |
P/E: | -2.19 |
Earnings Date: | May 02, 2024 |
SharesOutstanding: | 131.18 mill |
Avg Daily Volume: | 1.154 mill |
RATING 2024-04-18 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.19 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.37x |
Company: PE -2.19 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.450 (-107.36%) $-6.56 |
Date: 2024-04-18 |
Expected Trading Range (DAY) |
---|
$ 5.57 - 6.65 ( +/- 8.82%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Catinazzo Thomas | Sell | 348 | Common Stock |
2024-03-27 | Bergstrom Donald A | Sell | 765 | Common Stock |
2024-03-27 | Rahmer Peter | Sell | 298 | Common Stock |
2024-03-27 | Adams Brian | Sell | 348 | Common Stock |
2024-01-29 | Rahmer Peter | Sell | 1 651 | Common Stock |
INSIDER POWER |
---|
87.60 |
Last 99 transactions |
Buy: 4 152 455 | Sell: 399 360 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $6.11 (-1.61% ) |
Volume | 2.77 mill |
Avg. Vol. | 1.154 mill |
% of Avg. Vol | 239.92 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $8.89 | N/A | Active |
---|
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.